异基因造血干细胞移植后血脂异常的发生机制及防治要点  

The pathogenesis and prevention of dyslipidemia after allogeneic hematopoietic stem cell transplantation

作　　者：董珈余 窦颖[1] Dong Jiayu;Dou Ying(Department of Hematology and Oncology,Children's Hospital of Chongqing Medical University,National ClinicalResearch Center for Child Health and Disorders,Ministry of Education Key Laboratory of Child Development and Disorders,Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity,Chongqing 400014,China)

机构地区：[1]重庆医科大学附属儿童医院血液肿瘤科,国家儿童健康与疾病临床医学研究中心,儿童发育疾病研究教育部重点实验室,儿童感染与免疫罕见病重庆市重点实验室,重庆400014

出　　处：《器官移植》2024年第6期977-982,共6页Organ Transplantation

基　　金：重庆市自然科学基金(CSTB2023NSCQ-MSX0212)。

摘　　要：异基因造血干细胞移植(allo-HSCT)是治疗多种血液系统及免疫系统疾病的有效手段,但术后存在感染、移植物抗宿主病等并发症。血脂异常是allo-HSCT后常见的并发症之一,与移植物抗宿主病、免疫抑制药应用、心血管疾病、代谢综合征等存在密切联系,allo-HSCT后造血重建与脂质代谢也有相关性。因此,本文就allo-HSCT后脂质代谢情况、allo-HSCT后影响血脂异常的机制与相关因素、血脂异常对allo-HSCT后并发症的影响、allo-HSCT后血脂异常的预防及治疗等方面进行综述,旨在探寻allo-HSCT后血脂异常的影响和意义,为allo-HSCT后血脂异常的防治提供参考。Allogeneic hematopoietic stem cell transplantation(allo-HSCT)is an effective treatment for a varietyof hematopoietic and immune system diseases,but it is associated with postoperative complications such as infection andgraft-versus-host disease.Dyslipidemia is one of the common complications after allo-HSCT,which is closely related tograft-versus-host disease,the use of immunosuppressants,cardiovascular diseases and metabolic syndrome,etc.Hematopoiesis reconstruction after allo-HSCT is also related to lipid metabolism.Therefore,this article reviews the lipidmetabolism after allo-HSCT,the mechanisms and related factors affecting dyslipidemia after allo-HSCT,the impact ofdyslipidemia on post-transplant complications,and the prevention and treatment of dyslipidemia after allo-HSCT,aimingto explore the impact and significance of dyslipidemia after allo-HSCT,and to provide references for the prevention andtreatment of dyslipidemia after allo-HSCT.

关 键 词：造血干细胞移植 血脂异常 移植物抗宿主病 造血重建 免疫抑制药 感染 脂质代谢 他汀类药物 

分 类 号：R457[医药卫生—治疗学] R344[医药卫生—临床医学]